Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 715 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cystic Fibrosis, Pulmonary Clear all
Completed Phase 1 Interventional

Hydroxychloroquine in Cystic Fibrosis

NCT00311883
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
hydroxychloroquine
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
16 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 30, 2008 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Not applicable Interventional Results available

Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions

NCT03938324
View directory record Official record
Conditions
Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer, Inflammatory Bowel Diseases, Stem Cell Transplant, Organ Transplant, Diabetes Mellitus, Type 1, Cystic Fibrosis
Interventions
PiCASO Intervention Group, Sham Comparator: Attention Control Group
Behavioral
Lead sponsor
Duke University
Other
Eligibility
16 Years to 22 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

NCT02508207
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Tezacaftor/Ivacaftor, Ivacaftor, Tezacaftor/Ivacaftor matching placebo, Ivacaftor matching placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 13, 2026, 5:12 PM EDT
Completed No phase listed Observational

Airway Clearance Therapy on Hyperpolarized 129Xenon and MRI

NCT03593434
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
hyperpolarized Xenon gas
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 21 Years
Enrollment
20 participants
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 13, 2026, 5:12 PM EDT
Terminated Phase 4 Interventional Results available

Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations

NCT03624101
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Symdeko, Ivacaftor and Symdeko
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects

NCT01768663
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lumacaftor, Ivacaftor, Ciprofloxacin, Itraconazole, Rifampin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 15, 2013 · Synced Oct 13, 2026, 5:12 PM EDT
Completed No phase listed Observational

Observational Trial of the Longitudinal Effects of CFTR Modulator Drugs

NCT04353752
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 13, 2026, 5:12 PM EDT
Recruiting Phase 2 Interventional

Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

NCT06364176
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Losartan, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
12 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Phase 4 Interventional Results available

Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis

NCT05740618
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Mannitol Inhalant Product
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements

NCT03534986
View directory record Official record
Conditions
Cystic Fibrosis, Bronchiectasis
Interventions
International Biophysics AffloVest, Hill-Rom The Vest, Respirtech inCourage, Electromed SmartVest
Device
Lead sponsor
International Biophysics Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Kissimmee, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Not applicable Interventional

Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience

NCT01013896
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Motivational Interviewing, Cystic Fibrosis Education
Behavioral · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
16 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 13, 2026, 5:12 PM EDT
Recruiting No phase listed Observational

Health Outcomes of Parents With Cystic Fibrosis-Aim 2

NCT06296394
View directory record Official record
Conditions
Cystic Fibrosis, Parenthood Status
Interventions
Parenthood
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
18
States / cities
Birmingham, Alabama • Denver, Colorado • Evanston, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 13, 2026, 5:12 PM EDT
Enrolling by invitation No phase listed Observational

Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs

NCT04930289
View directory record Official record
Conditions
Interstitial Lung Disease, COPD, Cystic Fibrosis, Pulmonary Fibrosis, Pulmonary Arterial Hypertension, Emphysema
Interventions
LungGuard, BAROGuard
Device
Lead sponsor
Paragonix Technologies
Industry
Eligibility
Not listed
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
14
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 13, 2026, 5:12 PM EDT
Completed No phase listed Observational

Observational Study Comparing Home to Office Spirometry

NCT05285410
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Chris Goss
Other
Eligibility
6 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
19
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Peoria, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 13, 2026, 5:12 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

VITamin D and OmegA-3 TriaL: Effects on Mammographic Density and Breast Tissue

NCT02239874
View directory record Official record
Conditions
Benign Breast Disease
Interventions
Vitamin D and fish oil placebo, Fish oil and vitamin D placebo, Vitamin D placebo and fish oil placebo, Vitamin D and fish oil
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years to 67 Years · Female only
Enrollment
3,894 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 13, 2026, 5:12 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Markers of Osteoporosis in Cystic Fibrosis

NCT03921060
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Denosumab
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 13, 2026, 5:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis

NCT01661491
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
3 Months to 4 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 13, 2026, 5:12 PM EDT
Completed No phase listed Observational Results available

Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic Fibrosis

NCT03801993
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Chris Goss
Other
Eligibility
2 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
26
States / cities
Palo Alto, California • Hartford, Connecticut • Washington D.C., District of Columbia + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

NCT01180634
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Aeroquin, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
95
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Phase 2 Interventional

A Study in Pediatric Patients With Cystic Fibrosis Lung Disease

NCT00130182
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
denufosol tetrasodium (INS37217)
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
5 Years to 7 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
3
States / cities
Denver, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 13, 2026, 5:12 PM EDT
Completed No phase listed Observational

Cystic Fibrosis Foundation (CFF) Biomarkers of Exacerbation

NCT00788359
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
5
States / cities
Denver, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

Rollover Study of VX-770 in Cystic Fibrosis Subjects

NCT01117012
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
36
States / cities
Birmingham, Alabama • Oakland, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

NCT01685801
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo-matched-to-ivacaftor tablet
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

NCT00981214
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
EUR-1008 (APT-1008)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Up to 7 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 13, 2026, 5:12 PM EDT